BioLargo Financial Statements From 2010 to 2024
| BLGO Stock | USD 0.19 0.01 5.00% |
Check BioLargo financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLargo's main balance sheet or income statement drivers, such as , as well as many indicators such as . BioLargo financial statements analysis is a perfect complement when working with BioLargo Valuation or Volatility modules.
BioLargo |
BioLargo OTC Stock Operating Margin Analysis
BioLargo's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current BioLargo Operating Margin | (1.16) % |
Most of BioLargo's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLargo is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, BioLargo has an Operating Margin of -1.1624%. This is 20.38% lower than that of the Chemicals sector and 163.52% lower than that of the Materials industry. The operating margin for all United States stocks is 78.9% lower than that of the firm.
BioLargo Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioLargo's current stock value. Our valuation model uses many indicators to compare BioLargo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioLargo competition to find correlations between indicators driving BioLargo's intrinsic value. More Info.BioLargo is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLargo by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLargo's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About BioLargo Financial Statements
BioLargo investors utilize fundamental indicators, such as revenue or net income, to predict how BioLargo OTC Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.